Fever-related ataxia: a case report of CAPOS syndrome by Stenshorne, Ida et al.
CASE REPORT Open Access
Fever-related ataxia: a case report of
CAPOS syndrome
Ida Stenshorne1,2* , Magnhild Rasmussen3, Panagiotis Salvanos4, Chantal M. E. Tallaksen5,2,
Laurence A. Bindoff6,7 and Jeanette Koht8,2
Abstract
Background: CAPOS (Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy and Sensorineural hearing loss) syndrome is
caused by the heterozygous mutation, c.2452G > A, in the ATP1A3 gene. Other mutations in this gene can cause a
spectrum of overlapping phenotypes including alternating hemiplegia of childhood, rapid onset dystonia parkinsonism,
early infantile epileptic encephalopathy and fever induced paroxysmal weakness and encephalopathy. The phenotype is
still mistaken for mitochondrial/metabolic disorders and follow up studies are scare.
Case presentation: We report a 20 year old Norwegian male with ataxia, sensorineural deafness and visual loss. Before
the age of five he experienced three fever related episodes of acute neurological deterioration when he temporarily lost
his acquired motor skills and developed persistent gait and limb ataxia. In childhood, he developed bilateral optic atrophy
and bilateral sensorineural hearing loss. Motor skills improved and at age 20 the patient showed a mild ataxia, hearing
loss and reduced vision. A c.2452G > A mutation in the ATP1A3 gene was identified and CAPOS syndrome was confirmed.
Conclusions: This is the first Norwegian patient reported with CAPOS syndrome. Our patient had a de novo, previously
identified ATP1A3 mutation. The combination of recurrent episodes of fever related ataxia, loss of motor skills in early
childhood, and early onset hearing and vision loss is typical of CAPOS syndrome. Previous reports suggest a gradual
progression of the disease after the initial episodes, while this patient showed a good outcome with improvement of
motor skills from adolescence long after the last deterioration episode.
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Background
CAPOS syndrome is an acronym for Cerebellar ataxia, Are-
flexia, Pes cavus, Optic atrophy, and Sensorineural hearing
loss (OMIM; 601,338) and was first described in three pa-
tients from a family published by Nicolaides et al. in 1996
[1]. Since then, more than 40 patients have been reported
[2–6]. The age of onset is between 6 months and 7 years
and the first symptoms are acute episodes of ataxic enceph-
alopathy or weakness triggered by febrile illness [2, 7]. Al-
most all patients have experienced one to three episodes of
acute neurological symptoms [2, 7, 8], which usually recov-
ered over days to months. Most patients have had a variable
degree of persisting ataxia and develop areflexia, bilateral
optic atrophy and sensorineural hearing loss over a few
years [2]. Pes cavus is reported in 30% of patients [2, 9] and
neuroimaging with cerebral magnetic resonance imaging is
reported as normal in nearly all patients [1, 2, 4–6, 8–11]
Demos et al. found a novel disease causing mutation
c.2452G >A (p.Glu818Lys) in the ATP1A3 gene, and subse-
quently the same mutation in this gene has been found in
all patients with the clinical diagnosis of CAPOS syndrome
[2, 7]. The mutation is known to be inherited in an auto-
somal dominant manner [5, 7, 9] and appears to be fully
penetrant [12].
The ATP1A3 gene encodes the alfa3 subunit of the
Na+/K+ -ATPase, an ion pump, responsible for restoring
neuronal membrane potential after depolarization and
for maintaining neuronal excitability [13]. The alfa3 sub-
unit is widely expressed in tissues such as the optic
nerve, various parts of the cochlea, cerebellar cortex and
nerves innervating muscle spindles [14–18]. Demos et al.
hypothesized that the mechanism was consistent with a
gain in function, and this has later been supported by
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Maas et al. [7, 8]. The defective ATPase appears to cause
leakage of sodium and potassium ions across the cell
membrane, which in turn leads to reduced neuronal excit-
ability [19]. Animal studies have shown that in mice with
a comparable defective ATPase, elevated temperature fur-
ther increases the leakage of Na+/K+ ions [19], offering an
explanation why fever may trigger the acute neurological
signs in this syndrome [2, 8]. Other disease causing vari-
ants of the ATP1A3 gene are known to cause: 1) Alternat-
ing hemiplegia of childhood (AHC); 2) Rapid onset
dystonia parkinsonism (RDP); 3) Early infantile epileptic
encephalopathy (EIEE); and 4) Fever induced paroxysmal
weakness and encephalopathy (FIPWE) [12, 20–23]. The
overlapping features make it difficult to differentiate these
ATP1A3-related disorders clinically [20]. Fever seems to
be the main trigger of the acute neurological symptoms in
patients with CAPOS syndrome as well as FIPWE [2, 5, 23].
Other ATP1A3-related disorders have additional precipitat-
ing factors (i.e. illness, alcohol, physical or psychological
events) [12, 21, 24].
Case presentation
The following detailed presentation is based on the pa-
tient medical journal and supplemented by the parents’
written diary.
The patient was the first of two children of healthy,
unrelated parents. He was born at term after an uncom-
plicated pregnancy and delivery. According to his par-
ents, he reached all milestones at the expected times and
showed a normal psychomotor development until the
age of 8 months. The patient had three episodes of acute
neurological symptoms requiring hospitalization at age
8 months, 18 months and 4 years. The symptoms and
signs included reduced consciousness, general hypo-
tonia, and ataxic movements that included problems
with balance. The diagnostic workup was unremarkable
in the acute setting, except for a slight elevation of C
reactive protein (CRP) lending support to the diagnosis
of a viral infection.
Episode one at 8 months of age
The patient was admitted after a few days of febrile ill-
ness. He was dehydrated and weak with signs of opisto-
tonus, but otherwise the examination was described as
normal. He was treated with intravenous antibiotics for
a suspected sepsis and his general condition rapidly
improved. After three days he was discharged with a
diagnosis of unspecific viral infection, and his parents
cannot remember any motor problems after this
hospitalization.
Episode two at 18months of age
The patient walked without support from the age of 14
months. At the age of 18 months, after a few days of
being unwell with fever, acute laryngitis and conjunctiv-
itis, he suddenly lost the ability to walk, had poor bal-
ance and uncoordinated extremities. The parents also
described an episode two days before admission of re-
duced consciousness with additional abnormal body
movements and hyperextension of his neck. His condi-
tion improved rapidly without specific treatment, and he
was discharged with a diagnosis of nonspecific viral in-
fection. Following discharge he had problems with
motor skills: it took 2 weeks before he started to crawl, 4
weeks before he gradually started to walk, and 6 months
until he could walk without support. His gait ataxia per-
sisted after this episode.
Age 2–4 years
Due to problems with balance and poor hearing, the pa-
tient was seen by a pediatric neurologist at age 2 years
and 9months. Examination was normal except of cere-
bellar deficits with a prominent trunk and gait ataxia,
and therefore his gait was unstable and broad based and
he was unable to jump. Deep tendon reflexes were ab-
sent. Electroencephalogram, blood tests, cerebrospinal
fluid, as well as metabolic screening of blood and urine
were normal. Cerebral magnetic resonance imaging
(MRI) was also normal.
A diagnosis of bilateral secretory otitis was made and
paracentesis was performed. His hearing and speech im-
proved markedly after this procedure. The otoacustic
emission was reported as normal. Ophthalmologic
examination showed normal vision, but a mild horizon-
tal nystagmus and bilateral optic atrophy. From the age
of 3 years, the parents reported that the boy had
impaired vision.
Episode three at 4 years of age
The patient was again admitted to the hospital at the
age of 4. He had been unwell for a few days with fever
and an exanthema due to a possible childhood illness.
On admission he was described as hypotonic and unable
to stand, with ataxia in the trunk and limbs. His head
control and visual fixation were poor and he gave no eye
contact. His condition rapidly improved without specific
treatment. Over the next 6 months the motor skills
gradually improved, but the gait, trunk and limb ataxia
persisted.
The diagnostic odyssey (age 4–20 years)
In total, more than 100 consultations at different hospitals
were performed. Repeated investigations with normal
findings included nerve conductions, electromyography,
cerebrospinal fluid, muscle biopsy, metabolic tests in
blood and urine, MRI of the brain (at the age of 2, 4, 6
and 9 years), single gene tests (TIMM8A, Connexin 26,
Connexin 30, frataxin, ABHD1, POLG, otofelin, TL1, TK,
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ATP), array-cgh, electroencephalograms and in addition
different vision and hearing assessments.
At the age of 4 he was, in addition to the ataxia, diag-
nosed with bilateral auditory neuropathy due to a patho-
logical auditory brainstem response. The diagnosis of
Mohr-Tranebjærg syndrome was mentioned as a pos-
sible diagnosis, but was not genetically confirmed. From
the age of 5 the ataxia has been reported to gradually
improve.
At the age of 7 he was diagnosed with reduced vision.
His best spectacle corrected visual acuity with the age
appropriate test was 0.5 in both eyes with an obvious
“crowding” effect, and the contrast sensitivity with the
Hiding Heidi low contrast face test (Good Lite, IL, USA)
was slightly reduced at 2,5%. The visual evoked potential
and electroretinogram was at that time described as
normal.
Throughout childhood he was also investigated and
had different diagnoses due to concentration problems
and learning difficulties, but his behavioral issues im-
proved drastically at the age of ten, when he was taught
sign language. As an adolescent the patient received
cochlear implants bilaterally, and his school perfor-
mances improved after this.
Due to the bilateral cochlear implants no later MRI in-
vestigations after the age of nine have been performed.
At the age of 16, the patient was reevaluated by an
adult neurologist. At that time he was well functioning,
but with a mild gait and limb ataxia and significant
problems with hearing and vision due to known bilateral
sensorineural hearing loss and optic atrophy. In addition
he had a general areflexia.
Examination and investigations at the age of 20 years
The patient is well functioning and has completed high
school education. He still has a mild gait and limb ataxia,
which worsen when walking on uneven surfaces, and he is
not able to walk or stand in tandem (Additional file 1).
He has a slight intention tremor and dysmetria, but no
dysdiadochokinesis. Scale for the assessment and rating
of ataxia (SARA score) is 10 out of 40 points. Muscle
tone is normal, as is sensation, except for mildly im-
paired pain sensation distally. There is a general areflexia
and plantar reflexes are down going. He has slightly high
feet arches (Fig. 1), but no problems with his feet. He
has bilateral cochlear implants and is able to speak, al-
though speech is affected by his hearing impairment and
he prefers to use sign language. Spectacle corrected vis-
ual acuity is 0.1 in both eyes, and he has gaze evoked
horizontal nystagmus. Contrast sensitivity is reduced
further to 5%. Slitlamp examination revealed no anomaly
in the anterior segment, while dilated ophthalmoscopy
shows bilateral diffuse optic atrophy. Ultra widefield fun-
dus photography confirms the pale, atrophic optic
nerves with otherwise normal retina and vessels. Auto-
fluorescence imaging confirms the finding, showing loss
of nerve fibers on the optic disc that in normal individ-
uals give darker, hypofluorescent signal and revealing the
hyperfluorescent sclera and lamina cribrosa (Fig. 2).
Diagnostic exome sequencing of the patient and his par-
ents revealed a de novo mutation: c.2452G >A; p.Glu818Lys
in the ATP1A3 gene in the patient.
Discussion and conclusions
This is the first patient reported with CAPOS syndrome
in Norway. While previous reports have suggested grad-
ual progression of disease [2], our patient showed im-
provement of the ataxia from the age of five until the
age of 20 years. Our patient has four of the five main fea-
tures of CAPOS syndrome. He has high feet arches, but
no pes cavus. This is the most debated feature of the
syndrome and is present in only 30% of patients as op-
posed to 10% of the general population [2, 9]. We would
therefore support the suggestion that P should be omit-
ted and the acronym changed to CAOS syndrome [9]. In
addition to the well known features of CAPOS syn-
drome, our patient has bilateral horizontal nystagmus.
Until recently, unspecified nystagmus is reported in over
50% of all CAPOS syndrome patients and many of them
are specified as horizontal nystagmus [1, 2, 7–10, 25].
Nystagmus therefore seems to be a common feature of
the syndrome. During the first and second acute epi-
sodes opistotonus, abnormal body movements and
hyperextension of the neck were described. We believe
this has been dystonia. No videos or more objective de-
scriptions of these features were done in the medical
record. Dystonia and other hyperkinetic movements are
described in a few previously reported CAPOS syndrome
patients [7, 8, 24], but are more commonly described in
other ATP1A3-related disorders [26].
The specific ATP1A3 gene mutation found in this pa-
tient underlines the fact that this genetic mutation specif-
ically is confined to patients with CAPOS syndrome, and
is not found in association with other ATP1A3-related
syndromes [2].
Fig. 1 Left foot of the patient
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This patient went to more than 100 consultations and
underwent numerous investigations at different hospitals
in the space of 20 years. Many of these investigations are
expensive and many done repeatedly. Most test results
have been unremarkable and did not give much guid-
ance to the correct diagnosis. A long list of differential
diagnoses has been evaluated, but no explanation for his
signs and symptoms was found before a new clinical and
genetic evaluation was done. Many of the reported
CAPOS syndrome patients were initially suspected of
having other diseases such as; parainfectious cerebellitis
[8], encephalitis [2], metabolic disease [1, 8], mitochon-
drial disease [1, 2, 8, 9], episodic ataxia type 2 [8],
Miller-Fisher syndrome [9] or atypical Guillain-Barré syn-
drome [8], dominant optic atrophy plus (OPA1) [2, 9],
spinocerebellar ataxias [2], as well as many cerebellar
ataxic syndromes [1]. For many years the persisting ataxia,
hearing and vision loss in this patient were suspected to
be caused by a metabolic or a mitochondrial disorder.
CAPOS syndrome may resemble these disorders as they
all can be associated with multiorgan affection as well as
paroxysmal attacks of hypotonia, poor contact and poor
general condition, typically occurring with intercurrent
disease. Nevertheless, the positive clinical picture of our
patient with gradual improvement of the ataxia did not fit
well with a metabolic or a mitochondrial disorder where
the natural course would be a progressive ataxia. The
same applies to his normal test results that include meta-
bolic screening, MRI of the brain and previous genetic
workup. In the last decade there have been an increasing
number of reports of CAPOS syndrome [2–6, 11].
Fever is the main trigger of acute neurological symp-
toms of CAPOS syndrome and FIPWE [2, 5, 23], and
this is also seen in our patient. When investigating a
young child with fever related ataxia ATP1A3-related
disorders should therefore be considered.
As for most rare disorders, many diagnoses have been
suspected and checked for in this patient, which is also the
case for many of the other reported patients with CAPOS
syndrome [1, 2, 8, 9]. There are more than 5200 reported
monogenetic diseases in 2018 (http://omim.org/statistics/
entry) and it is impossible to know all the phenotypes.
Today we know that mutations in the ATP1A3 gene are
common in ataxia patients and should be tested for [27].
Monogenetic diseases is a difficult field in medicine, but
with rapidly evolving molecular genetic diagnostic tools, as
well as available and searchable databases, it has become
possible to diagnose these patients today, and will probably
be much easier in the future.
Additional file
Additional file 1: Video of the patient illustrating the ataxia
(MP4 40537 kb)
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